SLC5A2 and hydrops fetalis: In recent years, multiple randomised clinical trials have reported that sodium−glucose cotransporter 2 (SGLT2) inhibitors significantly reduce hospitalisations for acute decompensated HF in patients with type 2 diabetes (T2D) [3,4,5,6,7].